Wedbush Downgrades AnaptysBio (ANAB) to Neutral
- Wall Street comes off record highs ahead of big tech earnings
- Tesla (TSLA) Gains on Q2 Beat, Analysts Mostly Positive but Others Cautious
- China's Meituan (MPNGF) Plunges 17.6% to Push Hang Seng Index to 8-Month Lows as Heavy Selling Continues
- Raytheon (RTX) Gains on Beat-and-Raise, CEO Says Next War Will Be Fought in Cyber Space and Then Outer Space
- Dollar eases slightly with Fed in focus
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten downgraded AnaptysBio (NASDAQ: ANAB) from Outperform to Neutral.
Shares of AnaptysBio closed at $36.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Argus Downgrades AT&T (T) to Hold; Math 'Doesn't Work' on Dividend
- UPDATE: Benchmark Downgrades ATI Physical Therapy (ATIP) to Hold
- Citi Downgrades EQT AB (EQT:SS) (EQBBF) to Sell
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!